Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Alivus Life Sciences Limited (NSE: ALIVUS), ISIN INE03Q201024 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
ALIVUS last traded at ₹1392.00 (+0.63%), with a 52-week range of ₹830.00 to ₹1495.30 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 74.87%, FIIs 5.54%, DIIs 7.18%, mutual funds 5.65%.
EquiSense Score (ECS): 82/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.